Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/65503
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLópez Aspiroz, Elena
dc.contributor.authorCabrera Figueroa, Salvador Enrique
dc.contributor.authorValverde Merino, María Paz
dc.contributor.authorCarracedo Álvarez, Ángel
dc.date.accessioned2023-01-23T11:31:17Z-
dc.date.available2023-01-23T11:31:17Z-
dc.date.issued2019
dc.identifier.citationClin Drug Investig.2019;(39)11:1125-1131
dc.identifier.urihttps://hdl.handle.net/20.500.12530/65503-
dc.description.abstractAntiretroviral therapy has changed the history of HIV infection from a lethal disease to a chronic infection, with the emergence of long-term adverse effects. Herein we present a case of a heavily treated HIV-infected man in whom antiretroviral toxicity had been observed. The lopinavir/ritonavir plasma concentrations at standard doses were significantly above the recommended levels. Pharmacogenetic analysis revealed a polymorphism in the DRD3 gene associated with a decrease in the rate of drug metabolism. Additionally, the patient's low body mass index could have contributed to a greater degree of patient exposure to the drug. After the withdrawal of tenofovir disoproxil and the establishment of individualized protease inhibitor monotherapy at reduced doses, a decrease in the intensity of adverse events was observed, while the clinical outcomes were maintained. The pharmacokinetic-pharmacogenetic analysis was shown to be a tool of huge interest for the management and durability of antiretroviral therapy.
dc.language.isoen
dc.rightsopenAccess
dc.subject.meshAge Factors
dc.subject.meshDrug Substitution
dc.subject.meshHIV Infections
dc.subject.meshHIV Protease Inhibitors
dc.subject.meshHIV-1
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPharmacogenetics
dc.subject.meshPrecision Medicine
dc.subject.meshTreatment Outcome
dc.titleIndividualized Protease Inhibitor Monotherapy: The Role of Pharmacokinetics and Pharmacogenetics in an Aged and Heavily Treated HIV-Infected Patient.
dc.typeArtículo
dc.identifier.pubmedID31401737
dc.format.volume39
dc.format.page1125-1131
dc.identifier.e-issn1179-1918
dc.identifier.journalClinical drug investigation
dc.identifier.journalabbreviationClin Drug Investig
dc.identifier.doi10.1007/s40261-019-00829-x
dc.format.number11
dc.pubmedtypeCase Reports
dc.pubmedtypeJournal Article
Appears in Collections:Hospitales > H. U. Infanta Sofía > Artículos

Files in This Item:
File SizeFormat 
4220799.pdf460.27 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.